Hitkansut LLC v. United States
119 Fed. Cl. 258
Fed. Cl.2014Background
- Patent case involving U.S. Patent No. 7,175,722 on stress relief using multiple energy sources; government seeks invalidity under 35 U.S.C. §112 (enablement).
- Claims 1, 2, 6, and 11 at issue; claims 7, 8, and 14 previously ruled invalid under §101.
- Larson–Miller relationship governs time–temperature calculations; disclosure in the patent is challenged for errors and potential undue experimentation.
- Court previously held Claims 7, 8, 14 invalid for lack of eligibility; remaining issues debated enablement.
- Court concludes the disclosed Larson–Miller framework, with minor representational errors, enables the asserted claims; Grant of summary judgment: Claim 2 invalid under §112(4); other claims not invalidated.
- Independent Claim 1 and dependent Claims 2 and 6 relate to Larson–Miller parameters and energy strategies; Claim 11 stands as a separate independent claim; court orders remain consistent with prior rulings.
Issues
| Issue | Plaintiff's Argument | Defendant's Argument | Held |
|---|---|---|---|
| Whether Claims 1, 2, 6, 11 are enabled under §112(1). | Hitkansut argues minor errors do not defeat enablement. | United States contends substantial errors require undue experimentation. | Enabled; errors not preventing enablement. |
| Whether Claim 2 complies with §112(4) as a further limitation of Claim 1. | Hitkansut notes Larson–Miller parameters in Claim 2. | Government contends Claim 2 adds no new limitations beyond Claim 1. | Claim 2 invalid under §112(4). |
| Whether the breadth of the asserted claims defeats enablement. | Hitkansut argues Larson–Miller framework constrains scope. | Government argues overbreadth without support. | Not dispositive; enablement preserved by Larson–Miller context. |
Key Cases Cited
- PPG Indus., Inc. v. Guardian Indus. Corp., 75 F.3d 1558 (Fed. Cir. 1996) (harmless errors do not defeat enablement where skilled artisans can practice the invention)
- In re Wands, 858 F.2d 731 (Fed. Cir. 1988) (relevant factors for undue experimentation in enablement)
- Ariad Pharms., Inc. v. Eli Lilly & Co., 598 F.3d 1336 (Fed. Cir. 2010) (en banc discussion on breadth and enablement)
- ALZA Corp. v. Andrx Pharm., LLC, 603 F.3d 935 (Fed. Cir. 2010) (baseline expectations for enabling disclosures)
- Pfizer, Inc. v. Ranbaxy Labs. Ltd., 457 F.3d 1284 (Fed. Cir. 2006) (claim scope and enablement considerations)
- Nautilus, Inc. v. Biosig Instrs., Inc., 134 S. Ct. 2120 (S. Ct. 2014) (precision and notice under §112)